Epithelioid sarcoma: Opportunities for biology-driven targeted therapy

Jonathan Noujaim, Khin Thway, Zia Bajwa, Ayeza Bajwa, Robert G. Maki, Robin L. Jones, Charles Keller

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Epithelioid sarcoma (ES) is a soft tissue sarcoma of children and young adults for which the preferred treatment for localized disease is wide surgical resection. Medical management is to a great extent undefined, and therefore for patients with regional and distal metastases, the development of targeted therapies is greatly desired. In this review, we will summarize clinically relevant biomarkers (e.g., SMARCB1, CA125, dysadherin, and others) with respect to targeted therapeutic opportunities. We will also examine the role of EGFR, mTOR, and polykinase inhibitors (e.g., sunitinib) in the management of local and disseminated disease. Toward building a consortium of pharmaceutical, academic, and non-profit collaborators, we will discuss the state of resources for investigating ES with respect to cell line resources, tissue banks, and registries so that a roadmap can be developed toward effective biology-driven therapies.

Original languageEnglish (US)
Article number186
JournalFrontiers in Oncology
Volume5
Issue numberAug
DOIs
StatePublished - 2015

Keywords

  • BAF47
  • Epithelioid sarcoma
  • INI1
  • SMARCB1
  • SWI/SNF complex

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Epithelioid sarcoma: Opportunities for biology-driven targeted therapy'. Together they form a unique fingerprint.

  • Cite this

    Noujaim, J., Thway, K., Bajwa, Z., Bajwa, A., Maki, R. G., Jones, R. L., & Keller, C. (2015). Epithelioid sarcoma: Opportunities for biology-driven targeted therapy. Frontiers in Oncology, 5(Aug), [186]. https://doi.org/10.3389/fonc.2015.00186